T he article describes, for the first time, the targeted ablation of a cardiac protein that biochemical and physiological approaches had indicated as being important for the heart's response to β-adrenergic stimulation. The article brought the technology of gene targeting to the heart and helped establish the mouse as a useful and relevant model for studying normal and abnormal cardiovascular function.
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During much of the 20th century, cardiovascular research was firmly based on the 2 pillars of biochemistry and physiology. Biochemistry used reductionist approaches, dissecting a system into its component parts and studying them in isolated or reconstituted systems. Physiology, on the contrary, centered on intact animals, organs, and tissues in an attempt to understand how those systems functioned within the whole body context. These 2 disciplines brought many advances to cardiovascular research, but the ambiguous demonstrations needed to establish necessity, sufficiency, and causality remained elusive for many important cardiac proteins and functions. What is sufficient to mediate important short-term and long-term effects on cardiovascular function and adaptation? What is necessary? How might one establish direct causation in a whole animal context, in terms of a particular cardiac protein leading to disease or affecting muscle function? To address these types of questions, investigators had long used the tools of genetics in lower organisms to target a particular gene, either enhancing or ablating its function. Using these precise genetic tools, the subsequent effects on protein function could be measured in isolated cell types, tissues, organs, and the whole animal. Unfortunately, these earlier studies were largely restricted to genetically accessible systems such as worms, bacteriophages and virus, bacteria, yeasts, molds, and flies, whose cardiovascular systems were either absent or far removed from the 4-chambered, mammalian heart.
Much of the seminal biochemical work establishing the importance of phospholamban (PLN) and its interactions with the Ca 2+ pump in the cardiac sarcoplasmic reticulum (SR), termed the sarco/endoplasmic reticulum calcium ATPase (SERCA) was performed in the laboratory of Arnie Katz, beginning with the report in 1972 that cAMP-dependent kinases phosphorylate the cardiac SR. The Katz laboratory refined this observation and determined that cAMP-stimulated Ca 2+ uptake into the SR via SERCA was mediated by a 22-kDa phosphoprotein, which they named phospholamban, lamban from the Greek to receive. They postulated that PLN links βadrenergic stimulation and subsequent cAMP production to the regulation of Ca 2+ uptake by the SR. 1 Kinetic studies of SERCA revealed a complex biochemical reaction with intermediate reaction steps resulting in sequential formation and degradation of 2 phosphorylated intermediates. Binding of Ca 2+ and subsequently ATP to SERCA results in a conformational change in SERCA and ultimately translocation of Ca 2+ from the cytoplasm into the SR. Phosphorylation of PLN accelerated the rate-limiting steps of the ATPase reaction, that is, the binding and the release of Ca 2+ from the pump proper.
To first confirm and then understand the nature of this proposed PLN-SERCA interaction, the structure of PLN had to be determined. After purifying canine PLN and subsequently determining the cDNA sequence, the Tada laboratory demonstrated that monomeric PLN is a 6-kDa monomer that assembles into a pentamer with a molecular weight of 30 kDa. Pentamer assembly occurs with PLN phosphorylation because of a shift in the isoelectric point. 2 The secondary structure of PLN was predicted to form an amphipathic peptide, 52 amino acids in length with a hydrophilic, and thus cytoplasmic To mark the 60th birthday of Circulation Research , the editors have commissioned Circulation Research Classics, a series of commentaries highlighting seminal articles published in the journal over the past 6 decades that have importantly shaped cardiovascular research. Written by leading experts, Circulation Research Classics are intended to describe the impact of these articles on the field by putting them in a historical perspective. The concept of classic is inextricably linked to time-a classic is something that maintains its value regardless of its age. Thus, an important consideration in selecting the articles to be highlighted is that they have stood the test of time, which is the most reliable indicator of the value of scientific work. By looking back at the illustrious past of Circulation Research, we hope to promote a deeper appreciation of the contributions of this journal to the advancement of knowledge. amino terminus (domain I), and a hydrophobic carboxy terminus (domain II) embedded in the SR. Domain I contains 2 potentially phosphorylatable residues, Ser16 and Thr17, and 2 adjacent Arg residues at positions 13 and 14, forming a consensus sequence for protein kinase. The carboxy terminus is embedded in the SR and possesses 3 Cys residues, 3 Leu residues, and 2 Ile residues that together contribute to pentamer assembly. Cross-linking experiments with purified PLN and SERCA showed that the 2 proteins interact only when PLN is unphosphorylated and SERCA is in the Ca 2+ -free state. PLN binds near the active phosphorylation site on SERCA and suppresses ATPase activity. Phosphorylation of PLN causes dissociation of the pentamer from SERCA with a subsequent increase in ATPase activity and augmented uptake of Ca 2+ into the SR. 3 Although the initial descriptions of PLN focused on protein kinase A phosphorylation, PLN can also be phosphorylated by Ca 2+ -calmodulin (CaM) dependent protein kinases at Thr17, protein kinase C at Ser10, and c-GMP-dependent protein kinase at Ser16. To counterbalance these phosphorylation sites, the SR also contains intrinsic protein phosphatase activity that can dephosphorylate cAMP and Ca 2+ -CaM kinase-dependent sites on PLN. 4 Biochemical experiments showed that dephosphorylated monomeric PLN inhibits Ca 2+ uptake, with PLN phosphorylation and pentamer assembly releasing this inhibition. 5 These initial discoveries of the basic interactions between PLN and SERCA and the role of β-adrenergic signaling in this system depended on the enzymatic and biochemical techniques at that time, including synthesized proteins, site-directed mutagenesis, phosphor-and epitope-specific antibodies, reconstituted liposomes, and directed expression in heterologous cell systems. However, PLN is not the sole myocardial protein to become phosphorylated as a result of β-adrenergic stimulation because cardiac troponin I, myosinbinding protein C, and phospholemman also respond to βagonists in a similar fashion. What could not be determined using the available assays of the times were the relative contributions of these phosphoproteins to overall myocardial performance.
Targeted Ablation of the Phospholamban Gene Is Associated With Markedly Enhanced Myocardial Contractility and Loss of β-Agonist Stimulation
The solid foundation of biochemical data on protein-protein interactions and elegant structure-function analyses set the stage for extension of wet bench biochemistry to the intact animal. In 1987, during a postdoctoral fellowship in Oliver Smithies laboratory, Tom Doetschman achieved success in targeting a gene in mouse embryonic stem cells 6 and was recruited to Cincinnati soon after. The application of mammalian gene targeting the heart was accelerated because 2 scientists from different backgrounds and approaches were afforded the opportunity to develop significant scientific collaborations. Kranias quickly realized the potential that gene targeting had in cardiovascular research and used a sabbatical with Doetschman to begin the targeted ablation of PLN, with experiments designed to answer 2 basic questions: first, does PLN play an important role in the regulation of basal cardiac function and second, does PLN indeed mediate myocardial responses to β-adrenergic stimulation?
Mice homozygous for the targeted allele were viable and present in the expected Mendelian ratio, and there was no evidence of PLN mRNA or protein. The PLN nulls were indistinguishable from wild-type littermates and had similar body weight, heart weight, heart rate, and blood pressure. However, an elegant perfused working heart preparation designed by Drs Ingrid L. Grupp and Gunther Grupp at the University of Cincinnati College of Medicine 7 revealed striking differences in basal cardiac function in the PLN nulls. In comparison with wild-type, PLN nulls had similar cardiac heart rate and cardiac output, yet higher developed left ventricular pressure and lower left ventricular end-diastolic pressure. The maximum change in pressure over time (±dP/dt) was higher in the PLN nulls as well, indicating augmented contractility and relaxation. The addition of the β-agonist isoproterenol into the myocardial perfusate resulted in an increase in all these parameters for wild-type hearts, with no response observed in the PLN null hearts. Interestingly, the level of ±dP/dt achieved by wild-type hearts at maximal β-adrenergic stimulation was identical to that of the PLN null hearts at baseline. In essence, at baseline the PLN-deficient hearts performed as if under maximal β-adrenergic stimulation, suggesting that PLN is a key protein mediating the β-agonist response in the mouse heart. Stated another way, PLN negatively modulates basal myocardial contractility, with the release of inhibition upon PLN phosphorylation (Figure 1 ). 8 These effects are shown schematically in Figure 2 . The situation is necessarily more complex in the intact animal, where increased plasma catecholamines in the setting of heart failure are associated with the poorest prognosis. Paradoxically, β-adrenergic blockade is now a mainstay of heart failure therapy after another landmark article from the 1990s demonstrated improved survival and fewer cardiac-related hospitalizations in advanced heart failure patients treated with carvedilol. 9 The extension of cardiovascular investigations and genetic manipulations to mammalian species necessitated the development of specialized techniques for phenotypic analysis. The working heart preparation, assembled by the Grupps essentially from scratch, assesses cardiac function in isolation from the whole animal. The advantage of the working heart preparation is that ventricular loading conditions may be precisely manipulated and a variety of cardioeffective compounds added to the perfusate solution. However, this ex vivo technique isolates the heart from the effects of pericardial enclosure and eliminates cardiorespiratory interactions. Homeostatic mechanisms driven by the autonomic nervous system such as heart rate, blood pressure, and systemic vascular resistance are likewise removed from consideration. Finally, both the working heart preparation and in vivo instrumentation of the left ventricle are terminal procedures, preventing the longitudinal assessment of a single animal over time. At the time of the initial PLN studies, mouse echocardiography was still being developed. The earliest applications to mouse imaging were accomplished with lower frequency transducers intended for human scanning, resulting in poor spatial and temporal resolution in the mouse heart. 10 The rapid adoption of genetically modified mice for the study of cardiac disease was a key driver in the development of high-frequency ultrasound transducers, now widely available for mouse echocardiography, as well as magnets customized for mouse MRI.
The data contained within Luo et al 8 led to an explosion of work on PLN and its associated proteins. The concept that calcium homeostasis in the cardiomyocyte is largely controlled by PLN's reversible inhibition of SERCA has been augmented by data showing that small, ubiquitin-like modifier (SUMO), S100A1, and the histidine-rich Ca 2+ -binding protein also have functional roles in regulating SERCA's activity. In addition, PLN's reversible phosphorylation implies an additional layer of complexity and possible therapeutic targets via the targeting of its specific phosphatase. Most or all these proteins have also had their functionality explored by loss-or gain-offunction genetic experiments in the mouse, and the concept of targeting this regulatome 11 has been a focus of laboratories in academic institutions, biotechnology, and major pharmaceutical companies with ≈1000 articles published because the initial PLN ablation was reported.
A major advantage of the system, as illustrated by Luo et al, 8 was establishing a stable, animal model that could be subsequently manipulated. The Kranias laboratory established that their mouse, when bred to certain mouse models of heart failure, led to decreased morbidity, rescued aspects of the pathology, and increased lifespan in the face of continued cardiac insult. 12 These breeding strategies quickly assumed major importance as the number and sophistication of mouse models of cardiac disease increased exponentially and the testing of potential therapeutic targets began.
These approaches and a myriad of others encompassed by the hundreds of articles stemming from the original principles illustrated by this cardiovascular study have resulted in an intense focus on the components regulating SR Ca 2+ homeostasis. The article's data resulted in the initiation of searches for PLN mutations and targeted therapies, and indeed, a number of laboratories are currently engaged in screens directed at identifying small molecules that can affect regulatome activity. Confirmation of the importance of PLN in the maintenance of cardiac homeostasis has been achieved by demonstrating rescue of a rat model of heart failure using RNA interference of PLN, with dimeric cardiotropic adenoassociated virus vector used to deliver RNA interference via intravenous injection. 13 A gene therapy-based, clinical trial was launched in 2007. Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) is a multicenter trial designed to deliver SERCA2a cDNA, using an associated adenovirus vector, to patients with advanced heart failure. Both safety and efficacy have been/are being evaluated in this phase I/phase II trial. 14, 15 The phase I data showed acceptable safety in a 12-month follow-up and the phase II trial, with 39 patients, demonstrated significant benefits, including increased time to clinical events, decreased frequency of significant cardiovascular events, and a substantial decrease in the mean duration of cardiovascular hospitalizations. 15, 16 These initial data were compelling and the CUPID-2b trial, with a target enrollment of 200, is currently recruiting (http://www. clinicaltrials.gov/ct2/show/NCT01643330?term=serca2a&ra nk=3).
Although these initial results are promising and validate the importance and potential clinical value of treating the regulatome complex as a pharmaceutical target, a note of caution is appropriate. The era of modern experimental investigation of PLN was ushered in by Luo et al. 8 By necessity, all those data and the overwhelming majority of subsequent data were obtained using mouse models, which often were subjected to defined surgical, physical, or pharmacological stresses. However, there are numerous important differences between mouse and human cardiac physiology, including intrinsic heart rate, contractile protein complement, duration of the action potential, and the critical channels that underlie ion homeostasis. In a subsequent publication, the Kranias laboratory reported a dilated cardiomyopathy phenotype in patients homozygous for an L39stop mutation. Neither PLN mRNA nor protein could be isolated from the explanted heart of one such patient who required cardiac transplantation. Thus, the consequences of PLN deficiency in mouse and human are divergent, with hypercontractility in the former and dilated cardiomyopathy in the latter. 17 The appropriateness of the mouse as a model for generating clinical trials always needs to be considered, the most recent relevant example being the startling findings of Seok et al 18 demonstrating just how inappropriate the mouse is as a model for the human inflammatory stress response.
Mitigating these caveats are the positive initial data from the clinical trials, implying that much of the mouse data supporting clinical trials are in fact relevant to human disease. Although the final answers are still years away, there is no doubt that the article published in Circulation Research 20 years ago opened new doors to our understanding inotropic control of cardiovascular function and will ultimately result in the translation of that knowledge to therapeutic development.
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